Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries
Authors:
- Brian GodmanBGBrian Godman
- Anna BucsicsABAnna Bucsics
- Thomas BurkhardtTBThomas Burkhardt
- Manuela SchmitzerMSManuela Schmitzer
- Björn WettermarkBWBjörn Wettermark
- Peter WieningerPWPeter Wieninger
- 1 April 2010
- journal article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 10 (2) , 199-207
Abstract
To assess the utilization of renin-angiotensin drugs, including combinations, in Austria in practice given the limited availability of diuretics, as well as the impact of recent reforms and initiatives on the utilization and expenditure of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), following prescribing restrictions on ARBs immediately after their introduction. Utilization of dispensed prescriptions in ambulatory care was captured from 2001 to 2007 using defined daily doses as well as defined daily doses/1000 inhabitants/day for patients covered by the social health-insurance system. The data were provided by the internal data warehouse of Hauptverband der Osterreichischen Sozialversicherungsträger. Total costs in Euros were used for the analysis to facilitate comparisons with earlier studies. There was appreciable utilization of fixed-dose diuretic combinations at between 36 and 38% of all renin-angiotensin products, in line with expectations. The reduction in expenditure/defined daily dose for originator and generic ACEis and their combinations is, again, in line with expectations, mirroring earlier findings for proton pump inhibitors and statins. ARB utilization was just under 27% of all renin-angiotensin products. This is higher than the low utilization rates seen with atorvastatin following its prescribing restrictions, and may reflect the difficulties if restrictions are based on subjective criteria. ARB utilization rates were lower or similar to other countries, who have implemented a different range of demand-side reforms to limit their prescribing with the advent of generic ACEis. The results confirm the successful implementation of the latest pricing policies and demand-side measures for generics and originators in Austria. We believe the prescribing restrictions for ARBs reduced their utilization in practice and offer an alternative approach to other demand-side measures.Keywords
This publication has 37 references indexed in Scilit:
- Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implicationsExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevanceExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Insight into recent reforms and initiatives in Austria: implications for key stakeholdersExpert Review of Pharmacoeconomics & Outcomes Research, 2008
- Recent National and Regional Drug Reforms in SwedenPharmacoEconomics, 2008
- Having Your Cake and Eating ItPharmacoEconomics, 2008
- The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a reviewInternational Journal Of Clinical Practice, 2007
- Switching statins in Norway after new reimbursement policy – a nationwide prescription studyBritish Journal of Clinical Pharmacology, 2007
- Reference drug programs: Effectiveness and policy implicationsHealth Policy, 2007
- Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicineBMJ, 2006